Status:
UNKNOWN
Epigenetic Tools as Prognostic Predictors in Covid19
Lead Sponsor:
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Collaborating Sponsors:
Istanbul University
Conditions:
Prognosis
Eligibility:
All Genders
18-65 years
Brief Summary
The necessity for early detection and hence improving the outcome of treatment of pneumonia is critical especially SARS-CoV-2 induced cases. This work was designed to evaluate the potential applicatio...
Detailed Description
The objectives of this observational study are 1) To investigate why COVID-19 infection causes different biological behavioral patterns in individuals, 2) To determine the role of epigenetic mechanism...
Eligibility Criteria
Inclusion
- All patients between the ages of 18 and 65 included will suffer from COVID 19, and specific treatment should not yet be initiated.
- COVID 19 diagnosis of patients will be based on full medical history, thorough clinical examination, radiological imaging, laboratory assessment, and SARS-CoV-2 analysis by RT-PCR.
Exclusion
- People with chronic lung disease or previous AC surgery
- People with immune deficiency or cancer patients
- Patients receiving immunosuppressive therapy for autoimmune disease
- People with neurological diseases affecting the respiratory muscles, such as hypotonia.
Key Trial Info
Start Date :
May 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04411563
Start Date
May 21 2020
End Date
December 1 2020
Last Update
June 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Istanbul, Turkey (Türkiye), 34147